Beijing Aosaikang Pharmaceutical Co., Ltd. (SHE:002755)

SHE:002755 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	1,801	1,741	1,430	1,859	3,041	3,719
Other Revenue	37.05	37.05	13.77	13.61	65.22	63.37
Revenue	1,838	1,778	1,443	1,873	3,107	3,783
Revenue Growth (YoY)	18.30%	23.15%	-22.92%	-39.72%	-17.87%	-16.29%
Cost of Revenue	340.63	333.53	277.51	245.7	277.05	311.44
Gross Profit	1,497	1,444	1,166	1,627	2,830	3,471
Selling, General & Admin	1,182	1,151	973.24	1,333	2,159	2,439
Research & Development	172.82	177.32	472.01	588.84	324.45	255.89
Other Operating Expenses	25.81	21.83	15.67	24.89	41.19	51.99
Operating Expenses	1,382	1,350	1,456	1,940	2,520	2,739
Operating Income	114.75	94.55	-290.49	-313.2	309.73	732.55
Interest Expense	-2.43	-2.64	-2.81	-2.76	-3.99	-2.96
Interest & Investment Income	28.25	30.99	26.78	39.89	43.72	36.58
Currency Exchange Gain (Loss)	1.37	1.37	0.96	0.07	-0.02	-0.06
Other Non Operating Income (Expenses)	-3.22	-1.8	-3.19	-1.89	-0.08	-1.77
EBT Excluding Unusual Items	138.71	122.46	-268.75	-277.89	349.36	764.35
Gain (Loss) on Sale of Investments	14.63	12.73	12.5	1.68	2.39	-
Gain (Loss) on Sale of Assets	-0.16	-0.03	0.03	0.21	0.3	-0.02
Asset Writedown	-3.48	-3.06	-5.7	-20.79	-0.86	-0.26
Other Unusual Items	24.72	19.35	60.99	34.29	54.87	57.14
Pretax Income	174.43	151.45	-200.93	-262.5	406.07	821.2
Income Tax Expense	21.36	22.98	6.55	3.7	25.51	95.83
Earnings From Continuing Operations	153.07	128.47	-207.48	-266.21	380.56	725.37
Minority Interest in Earnings	30.41	31.82	58.95	40.38	-0.66	-3.74
Net Income	183.48	160.29	-148.53	-225.83	379.91	721.63
Net Income to Common	183.48	160.29	-148.53	-225.83	379.91	721.63
Net Income Growth	-	-	-	-	-47.35%	-7.60%
Shares Outstanding (Basic)	908	943	928	941	927	925
Shares Outstanding (Diluted)	908	943	928	941	927	925
Shares Change (YoY)	-4.03%	1.57%	-1.34%	1.55%	0.16%	-0.49%
EPS (Basic)	0.20	0.17	-0.16	-0.24	0.41	0.78
EPS (Diluted)	0.20	0.17	-0.16	-0.24	0.41	0.78
EPS Growth	-	-	-	-	-47.44%	-7.14%
Free Cash Flow	196.44	180.94	-155.89	-203.27	433.95	380.7
Free Cash Flow Per Share	0.22	0.19	-0.17	-0.22	0.47	0.41
Dividend Per Share	0.120	0.120	-	-	0.100	0.200
Dividend Growth	-	-	-	-	-50.00%	-9.09%
Gross Margin	81.46%	81.24%	80.77%	86.88%	91.08%	91.77%
Operating Margin	6.24%	5.32%	-20.13%	-16.73%	9.97%	19.37%
Profit Margin	9.98%	9.02%	-10.29%	-12.06%	12.23%	19.08%
Free Cash Flow Margin	10.69%	10.18%	-10.80%	-10.85%	13.97%	10.06%
EBITDA	188.45	169.84	-208.79	-224.03	401.33	825.17
EBITDA Margin	10.26%	9.55%	-14.46%	-11.96%	12.92%	21.81%
D&A For EBITDA	73.7	75.3	81.7	89.17	91.6	92.62
EBIT	114.75	94.55	-290.49	-313.2	309.73	732.55
EBIT Margin	6.24%	5.32%	-20.12%	-16.73%	9.97%	19.37%
Effective Tax Rate	12.25%	15.17%	-	-	6.28%	11.67%
Revenue as Reported	1,838	1,778	1,443	1,873	3,107	3,783

Source: S&P Global Market Intelligence. Standard template. Financial Sources.